Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19414372 | 0.81 | TRPV1 (0.48) | PDE10A | |
| SCHEMBL2616771 | 0.77 | CYP2A6 (0.59) | CYP19A1IMPDH2 | |
| SCHEMBL30969150 | 0.77 | CYP2A6 (0.59) | CYP19A1IMPDH2 | |
| SCHEMBL22685142 | 0.77 | PDE10A (0.42) | PDE10ACYP19A1IMPDH2ROCK1 | |
| SCHEMBL23396668 | 0.76 | PDE10A (0.43) | PDE10ACYP19A1IMPDH2ROCK1 | |
| SCHEMBL21363718 | 0.73 | CYP19A1 (0.41) | PDE10ACYP19A1IMPDH2ROCK1 | |
| SCHEMBL16274073 | 0.73 | CYP17A1 (0.51) | CYP19A1 | |
| SCHEMBL13615233 | 0.71 | PRKCZ (0.53) | CYP19A1IMPDH2ROCK1 | |
| SCHEMBL24621868 | 0.70 | CYP2A6 (0.54) | CYP19A1IMPDH2 | |
| SCHEMBL13670757 | 0.70 | CYP2A6 (0.54) | CYP19A1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PDE10A 2051/4885CYP19A1 3969/4885IMPDH2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.